A-oh! Teneo! @teneobio BCMA bispecific showing awesome 80% ORR at highest doses, q 3 week dosing, looks safe and ok to give with low GFR! 🙌 So happy to have this study open at UCSF Helen Diller Family Comprehensive Cancer Ctr Congrats to Cesar Rodriguez, MD (Myelomatips.com) #mmsm #ASH20

A new kid in the block has arrived in the immunotherapy world of myeloma. TNB-383B! @teneobio AbbVie Plasma Cell Pete Nina Shah ravi vij @adsouza_md Shaji Kumar Ben Buelow Wake Forest Baptist - Comprehensive Cancer Center ASH #mmsm #ASH20

Beyond first-gen BCMA bispecifics: the Baby Yodas are looking good at #ASH20 #mmsm

Novel Triple Chain BCMA bispecific TNB-383B presented by Cesar Rodriguez, MD (Myelomatips.com) at #ASH20 with 80% ORR with %80 VGPR or better with durable responses up to 39 weeks. No CRS Grade 3. Looking good #mmsm